Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

被引:23
|
作者
Facchinetti, Fabrizio [1 ]
Civelli, Maurizio [1 ]
Singh, Dave [2 ]
Papi, Alberto [3 ]
Emirova, Aida [4 ]
Govoni, Mirco [4 ]
机构
[1] Corp Preclin R&D, Parma, Italy
[2] Manchester Univ NHS Fdn Hosp Trust, Med Evaluat Unit, Manchester, Lancs, England
[3] Univ Ferrara, Dept Translat Med, Resp Med, Ferrara, Italy
[4] Global Clin Dev, Parma, Italy
关键词
phosphodiesterase 4 inhibitors (PDE4i); asthma; COPD-chronic obstructive pulmonary disease; inhaled administration; inflammation; SURFACTANT PROTEIN-D; METERED-DOSE INHALER; PHOSPHODIESTERASE-4; INHIBITOR; EOSINOPHILIC INFLAMMATION; PRECLINICAL PHARMACOLOGY; TRIPLE THERAPY; CYCLIC-AMP; ROFLUMILAST; COPD; CHF6001;
D O I
10.3389/fphar.2021.740803
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with this latter being the major cause of deaths. Despite differences in etiology and symptoms, a common feature of asthma and COPD is an underlying degree of airways inflammation. The nature and severity of this inflammation might differ between and within different respiratory conditions and pharmacological anti-inflammatory treatments are unlikely to be effective in all patients. A precision medicine approach is needed to selectively target patients to increase the chance of therapeutic success. Inhibitors of the phosphodiesterase 4 (PDE4) enzyme like the oral PDE4 inhibitor roflumilast have shown a potential to reduce inflammatory-mediated processes and the frequency of exacerbations in certain groups of COPD patients with a chronic bronchitis phenotype. However, roflumilast use is dampened by class related side effects as nausea, diarrhea, weight loss and abdominal pain, resulting in both substantial treatment discontinuation in clinical practice and withdrawal from clinical trials. This has prompted the search for PDE4 inhibitors to be given by inhalation to reduce the systemic exposure (and thus optimize the systemic safety) and maximize the therapeutic effect in the lung. Tanimilast (international non-proprietary name of CHF6001) is a novel highly potent and selective inhaled PDE4 inhibitor with proven anti-inflammatory properties in various inflammatory cells, including leukocytes derived from asthma and COPD patients, as well as in experimental rodent models of pulmonary inflammation. Inhaled tanimilast has reached phase III clinical development by showing promising pharmacodynamic results associated with a good tolerability and safety profile, with no evidence of PDE4 inhibitors class-related side effects. In this review we will discuss the main outcomes of preclinical and clinical studies conducted during tanimilast development, with particular emphasis on the characterization of the pharmacodynamic profile that led to the identification of target populations with increased therapeutic potential in inflammatory respiratory diseases.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] An inhibitor of RORγ for chronic pulmonary obstructive disease treatment
    Harshada Desai
    Megha Marathe
    Varada Potdar
    Prabhakar Tiwari
    Ashwini Joshi
    Sheetal R. Kadam
    Arti Rajesh Joshi
    Abhay Kulkarni
    Vikram Bhosale
    Avinash Hadambar
    Bhavik Lodhiya
    Venkatesha Udupa
    Dayanidhi Behera
    Sachin S. Chaudhari
    Sanjib Das
    Malini Bajpai
    Nagaraj Gowda
    Pravin S. Iyer
    Scientific Reports, 12
  • [42] Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease
    Rabe, Klaus F.
    BRITISH JOURNAL OF PHARMACOLOGY, 2011, 163 (01) : 53 - 67
  • [43] Treatment of Chronic Obstructive Pulmonary Disease with Roflumilast, a New Phosphodiesterase 4 Inhibitor
    Gross, Nicholas J.
    Giembycz, Mark A.
    Rennard, Stephen I.
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2010, 7 (02) : 141 - 153
  • [44] PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease
    Kilty, Lain
    Clarke, Nick
    Fairmain, David
    Lamb, David
    Mathias, John
    Millan, David
    Wright, Karen
    Perros-Huguet, Christelle
    Yeadon, Mike
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [45] An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma
    Al-Sajee, Dhuha
    Yin, Xuanzhi
    Gauvreau, Gail M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (05) : 609 - 620
  • [46] Discovery of LEO 39652 a novel PDE4 inhibitor for topical treatment of atopic dermatitis
    Larsen, J.
    Lambert, M.
    Nielsen, S. F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S115 - S115
  • [47] ABC of chronic obstructive pulmonary disease - Pharmacological management - inhaled treatment
    Currie, Graeme P.
    Lipworth, Brian J.
    BRITISH MEDICAL JOURNAL, 2006, 332 (7555): : 1439 - 1441
  • [48] Inhaled corticosteroids and chronic obstructive pulmonary disease
    Sapey, E
    Langford, NJ
    Kendall, MJ
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2000, 25 (04) : 235 - 238
  • [49] Inhaled corticosteroids for chronic obstructive pulmonary disease
    Cazzola, Mario
    Rogliani, Paola
    Novelli, Lucia
    Matera, Maria Gabriella
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (18) : 2489 - 2499
  • [50] Inhaled Anticholinergics for Chronic Obstructive Pulmonary Disease
    Singh, Sonal
    Furberg, Curt D.
    ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (10) : 920 - 922